ISRCTN79243381进行中（未招募）1 期
A phase Ib study to assess the safety and immunogenicity of a recombinant adenovirus-based vaccine against plague in Uganda (PlaVac Uganda)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Willing and able to give informed consent for participation in the trial
- •2. Male or female aged between 18-49 years old inclusive at enrolment (first vaccination visit)
- •3. In good health as determined by:
- •3.1. Medical history (as determined by verbal medical history)
- •3.2. Physical examination
- •3.3. Clinical judgment of the investigators
- •4. Female participants of childbearing potential must be willing to ensure that they use effective contraception during the trial and for 3 months after the last vaccination
- •5. Female participants of childbearing potential must have a negative pregnancy test on the day(s) of screening and vaccination
- •6. Able to attend the scheduled visits and comply with all study procedures
- •7. Agrees to refrain from donating blood for the duration of the trial
- •8. Clinically acceptable baseline screening results (includes vital signs, physical examination, urinalysis, and laboratory results)
- •9. In the Investigator’s opinion, is able and willing to comply with all trial requirements
排除标准
- •1. Pregnancy, lactating or planning pregnancy during the course of the trial
- •2 History of significant organ/system disease that could interfere with trial conduct or completion, including known history of significant disease in the following:
- •2.1. Cardiovascular disease, including congenital heart disease, previous myocardial infarction, valvular heart disease (or history of rheumatic fever), previous bacterial endocarditis, history of cardiac surgery (including pacemaker insertion), personal or family history of cardiomyopathy or sudden adult death
- •2.2. Respiratory diseases such as uncontrolled asthma and chronic obstructive pulmonary disease
- •2.3. Endocrine disorders such as diabetes mellitus and Addison’s disease
- •2.4. Significant renal or bladder disease
- •2.5. Biliary tract disease
- •2.6. Gastro-intestinal diseases such as inflammatory bowel disease, major abdominal surgery within the last two years, coeliac disease and liver disease (including hepatitis B or C infection)
- •2.7. Neurological diseases such as seizures and myasthenia gravis
- •2.8. Haematological problems such as coagulation problems or anaemia (haemoglobin < 12.5g/dl for females and < 13.5 g/dl and for males)
- •2.9. Metabolic diseases such as glucose-6-phosphate dehydrogenase deficiency
- •2.10. Psychiatric illness requiring hospitalisation or depression if the severity is deemed clinically significant by the Study Investigators
- •2.11. Known or suspected drug and/or alcohol misuse
- •2.12. Non-benign cancer, except squamous cell or basal cell carcinoma of the skin and cervical carcinoma in situ
- •3 Any other significant disease or disorder which, in the opinion of the Investigator, could:
- •3.1. Put the participant at risk because of participation in the trial
- •3.2. Influence the result of the trial
- •3.3. Impair the participant’s ability to participate in the trial
- •4. History of allergy to a vaccine or any component of the vaccines used in this study
- •5. History of anaphylaxis
- •6. Have any known or suspected impairment or alteration of immune function, resulting from, for example:
- •6.1. Congenital or acquired immunodeficiency
- •6.2. Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition
- •6.3. Autoimmune disease
- •6.4. Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy (including for more than 7 days consecutively within the previous 3 months)
- •7. Receipt of immunoglobulins or any blood product transfusion within 3 months prior to enrolment
- •8. Scheduled elective surgery or other procedures requiring general anaesthesia during the trial
- •9. Weight <50kg or a body mass index (BMI)greater than 35kg/m2
- •10. Previous occurrence of disease caused by Y pestis receipt of a vaccine against plague
- •11. Current active participation in another research study involving an investigational product (including receipt of an IMP within last 30 days) or where involvement in this study could im
研究者
相似试验
进行中（未招募）
1 期
A phase I study to evaluate safety and immunogenicity of recombinant protein candidate vaccine against SARS-CoV-2 in healthy volunteers.SARS-CoV-2MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862EUCTR2021-001411-82-ESABORATORIOS HIPRA, S.A.30
已完成
1 期
Safety and immunogenicity of a new tuberculosis (TB) vaccine (MVA85A) in healthy volunteers in Cape TowTuberculosisISRCTN17498868niversity of Oxford (UK)36
进行中（未招募）
不适用
A phase I/IIa study to assess the safety and immunogenicity of new malaria vaccine candidates AdCh63 MSP1 alone and with MVA MSP1 - A study of the safety and effectiveness of two new malaria vaccinesPlasmodium Falciparum MalariaEUCTR2009-012591-27-GBniversity of Oxford16
进行中（未招募）
1 期
A clinical trial to assess the safety, immune response, and protection against infection of novel malaria vaccines.Plasmodium falciparum infectionEUCTR2017-001049-28-GBniversity of Oxford, CTRG18
已完成
1 期
A phase 1 study of VLPCOV-01 in COVID-19 vaccinated healthy subjectsPrevention of infectious disease caused by SARS-CoV-2JPRN-jRCT2051210164obuaki Sato92